Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,255,690 papers from all fields of science
Search
Sign In
Create Free Account
GW 572016
Known as:
GW-572016
, GW572016
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
lapatinib
lapatinib ditosylate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
P. Medina
,
S. Goodin
Clinical Therapeutics
2008
Corpus ID: 1003727
Highly Cited
2008
Highly Cited
2008
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Chun-ling Dai
,
A. Tiwari
,
+12 authors
L. Fu
Cancer Research
2008
Corpus ID: 8197971
Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor…
Expand
Highly Cited
2006
Highly Cited
2006
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
G. Konecny
,
M. Pegram
,
+12 authors
D. Slamon
Cancer Research
2006
Corpus ID: 1131527
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here…
Expand
Review
2006
Review
2006
Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors
Michael H Nelson
,
C. Dolder
The Annals of Pharmacotherapy
2006
Corpus ID: 21622641
Objective: To review the pharmacology, pharmacokinetics, clinical trials, adverse effects, and drug interactions of lapatinib…
Expand
Highly Cited
2005
Highly Cited
2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients…
H. Burris
,
H. Hurwitz
,
+13 authors
N. Spector
Journal of Clinical Oncology
2005
Corpus ID: 33600591
PURPOSE This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with…
Expand
Review
2005
Review
2005
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
A. Arora
,
E. Scholar
Journal of Pharmacology and Experimental…
2005
Corpus ID: 33720
Cancer chemotherapy has been one of the major medical advances in the last few decades. However, the drugs used for this therapy…
Expand
Highly Cited
2005
Highly Cited
2005
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
W. Xia
,
Catherine M Gerard
,
Lei-hua Liu
,
N. Baudson
,
T. Ory
,
N. Spector
Oncogene
2005
Corpus ID: 31452110
Antibodies and small molecule tyrosine kinase inhibitors targeting ErbB2 exhibit distinct, noncross resistant mechanisms of…
Expand
Highly Cited
2005
Highly Cited
2005
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
N. Spector
,
W. Xia
,
+17 authors
S. Bacus
Journal of Clinical Oncology
2005
Corpus ID: 43353941
PURPOSE This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients…
Expand
Highly Cited
2004
Highly Cited
2004
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
E. Wood
,
A. Truesdale
,
+11 authors
L. Shewchuk
Cancer Research
2004
Corpus ID: 4827578
GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of…
Expand
Highly Cited
2002
Highly Cited
2002
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
W. Xia
,
R. Mullin
,
+6 authors
N. Spector
Oncogene
2002
Corpus ID: 24898799
Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE